Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations

Trial Profile

Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 Results of post hoc analysis (n=59) published in the Anticancer Research
    • 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 11 Sep 2012 Results with focus on secondary endpoints published in Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top